Outcomes in lower respiratory tract infections and the impact of antimicrobial drug resistance

Clinical Microbiology and Infection

Volumn 8, Issue SUPPL. 2, 2002, Pages 1-11

  Metlay, Joshua P ^a,c   Singer, Daniel E ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antimicrobial; Cohort studies; Morbidity; Mortality; Outcome; Patient outcomes; Pneumonia; Resistance

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; CEPHALOSPORIN; MACROLIDE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL PNEUMONIA; CHRONIC BRONCHITIS; CLINICAL STUDY; CLINICAL TRIAL; COMMUNITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DISEASE TRANSMISSION; DRUG COST; ECONOMIC ASPECT; HEALTH CARE COST; HUMAN; IN VITRO STUDY; INFECTION COMPLICATION; LOBAR PNEUMONIA; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MORTALITY; NONHUMAN; OUTCOMES RESEARCH; PATIENT CARE; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; SAMPLE SIZE; STREPTOCOCCUS PNEUMONIAE; SYMPTOMATOLOGY; TREATMENT INDICATION; TREATMENT OUTCOME;

BACTERIA (MICROORGANISMS); STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

EID: 0036398943     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1469-0691.8.s.2.4.x     Document Type: Article

References (35)

1. Epstein RS, Sherwood LM. From outcomes research to disease management: a guide for the perplexed. Ann Intern Med 1996; 124: 832-7.
2. Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA 1995; 273: 59-65.
3. Fine MJ, Stone RA, Singer DE et al. Processes and outcomes of care for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team (PORT) cohort study. Arch Intern Med 1999; 159: 970-80.
4. Dagan R, Klugman KP, Craig WA, Baquero F. Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. J Antimicrob Chemother 2001; 47: 129-40.
5. Fine MJ, Smith MA, Carson CA et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996; 275: 134-41.
6. Fine MJ, Auble TE, Yealy DM et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-50.
7. Austrian R, Gold J. Pneumococcal bacteremia with special reference to bacteremic pneumococcal pneumonia. Ann Intern Med 1964; 60: 759-76.
8. Meehan TP, Fine MJ, Krumholz HM et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997; 278: 2080-4.
9. Gleason PP, Meehan TP, Fine JM, Galusha DH, Fine MJ. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999; 159: 2562-72.
10. Dowell SF. The best treatment for pneumonia: new clues, but no definitive answers. Arch Intern Med 1999; 159: 2511-12.
11. Murray C, Lopez A, eds. The Global Burden of Disease: a Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Cambridge: Harvard University Press, 1996.
12. Halm EA, Fine MJ, Marrie TJ et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA 1998; 279: 1452-7.
13. Lave JR, Lin CC, Hughes-Cromick P, Fine MJ. The cost of treating patients with community-acquired pneumonia. Sem Respir Crit Care Medical 1999; 20: 189-98.
14. Fine MJ, Pratt HM, Obrosky DS et al. Relation between length of hospital stay and costs of care for patients with community-acquired pneumonia. Am J Med 2000; 109: 378-85.
15. Stahl JE, Barza M, DesJardin J, Martin R, Eckman MH. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia. Arch Intern Med 1999; 159: 2576-80.
16. Metlay JP, Atlas SJ, Borowsky LH, Singer DE. Time course of symptom resolution in patients with community-acquired pneumonia. Respir Med 1998; 92: 1137-42.
17. Metlay JP, Fine MJ, Schulz R et al. Measuring symptomatic and functional recovery in patients with community-acquired pneumonia. J Gen Intern Med 1997; 12: 423-30.
18. Bach PB, Brown C, Gelfand SE, McCrory DC. Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence. Ann Intern Med 2001; 134: 600-20.
19. Saint S, Bent S, Vittinghoff E, Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. JAMA 1995; 273: 957-60.
20. Felmingham D, Feldman C, Hryniewicz W et al. Surveillance of resistance in bacteria causing community-acquired respiratory tract infections. Clin Microbiol Infect 2002; 8(Suppl. 2): 12-42.
21. Craig WA. Pharmacokinetic/pharmacodynamic parameters. Rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-10; quiz 11-12.
22. Jacobs MR, Bajaksouzian S, Zilles A, Lin G, Pankuch GA, Appelbaum PC. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance study. Antimicrob Agents Chemother 1999; 43(8): 1901-8.
23. Metlay JP, Shea JA, Crossette LB, Asch DA. Tensions in antibiotic prescribing: pitting social concerns against the interests of individual patients. J Gen Intern Med 2002; 17: 87-94.
24. Pallares R, Gudiol F, Linares J et al. Risk factors and response to antibiotic therapy in adults with bacteremic pneumonia caused by penicillin-resistant pneumococci. N Engl J Med 1987; 317: 18-22.
25. Pallares R, Linares J, Vadillo M et al. Resistance to penicillin and cephalosporin and mortality from severe pneurnococcal pneumonia in Barcelona, Spain. N Engl J Med 1995; 333: 474-80.
26. Winston LG, Perlman JL, Rose DA, Gerberding JL. Penicillin-nonsusceptible Streptococcus pneumoniae at San Francisco General Hospital. Clin Infect Dis 1999; 29: 580-5.
27. Ewig S, Ruiz M, Torres A et al. Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae. Am J Respir Crit Care Med 1999; 159: 1835-42.
28. Turett GS, Blum S, Fazal BA, Justman JE, Telzak EE. Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high human immunodeficiency virus seroprevalence. Clin Infect Dis 1999; 29: 321-7.
29. Metlay JP, Hofmann J, Cetron MS et al. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2000; 30: 520-8.
30. Feikin DR, Schuchat A, Kolczak M et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-97. Am J Public Health 2000; 90: 223-9.
31. Kelley MA, Weber DJ, Gilligan P, Cohen MS. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis 2000; 31: 1008-11.
32. Harrison P, Lederberg J, eds. Antimicrobial Resistance: Issues and Options. Workshop Report. Washington DC: National Academy Press, 1998.
33. Snow V, Lascher S, Mottur-Pilson C. Evidence base for management of acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 2001; 134: 595-9.
34. Saint S, Flaherty KR, Abrahamse P, Martinez FJ, Fendrick AM. Acute exacerbation of chronic bronchitis: disease-specific issues that influence the cost-effectiveness of antimicrobial therapy. Clin Ther 2001; 23: 499-512.
35. Finch RG, Low DE. A critical assessment of published guidelines and other decision-support systems for the antibiotic treatment of community-acquired respiratory tract infections. Clin Microbiol Infect 2002; 8(Suppl. 2): 69-91.